RNAZ logo

TransCode Therapeutics (RNAZ) Company Overview

Profile

Full Name:

TransCode Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 8, 2021

Indexes:

Not included

Description:

TransCode Therapeutics focuses on developing RNA-based therapies for cancer treatment. Their lead product, RNAZ, aims to target and silence specific cancer-related genes, potentially improving patient outcomes. The company is dedicated to advancing innovative solutions in the field of oncology through cutting-edge RNA technology.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 16, 2022

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 4, 2024

Analyst ratings

Recent major analysts updates

Feb 7, 25 HC Wainwright & Co.
Buy
Feb 6, 25 HC Wainwright & Co.
Buy
Dec 18, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Oct 24, 24 HC Wainwright & Co.
Buy
Sep 6, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
May 29, 24 HC Wainwright & Co.
Buy
May 16, 24 HC Wainwright & Co.
Buy
Apr 16, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for TransCode Therapeutics?
  • Does TransCode Therapeutics pay dividends?
  • What sector is TransCode Therapeutics in?
  • What industry is TransCode Therapeutics in?
  • What country is TransCode Therapeutics based in?
  • When did TransCode Therapeutics go public?
  • Is TransCode Therapeutics in the S&P 500?
  • Is TransCode Therapeutics in the NASDAQ 100?
  • Is TransCode Therapeutics in the Dow Jones?
  • When was TransCode Therapeutics's last earnings report?
  • When does TransCode Therapeutics report earnings?
  • Should I buy TransCode Therapeutics stock now?

What is the ticker symbol for TransCode Therapeutics?

The ticker symbol for TransCode Therapeutics is NASDAQ:RNAZ

Does TransCode Therapeutics pay dividends?

No, TransCode Therapeutics does not pay dividends

What sector is TransCode Therapeutics in?

TransCode Therapeutics is in the Healthcare sector

What industry is TransCode Therapeutics in?

TransCode Therapeutics is in the Biotechnology industry

What country is TransCode Therapeutics based in?

TransCode Therapeutics is headquartered in United States

When did TransCode Therapeutics go public?

TransCode Therapeutics's initial public offering (IPO) was on July 8, 2021

Is TransCode Therapeutics in the S&P 500?

No, TransCode Therapeutics is not included in the S&P 500 index

Is TransCode Therapeutics in the NASDAQ 100?

No, TransCode Therapeutics is not included in the NASDAQ 100 index

Is TransCode Therapeutics in the Dow Jones?

No, TransCode Therapeutics is not included in the Dow Jones index

When was TransCode Therapeutics's last earnings report?

TransCode Therapeutics's most recent earnings report was on May 16, 2022

When does TransCode Therapeutics report earnings?

The date for TransCode Therapeutics's next earnings report has not been announced yet

Should I buy TransCode Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions